Sugi Predict

Sugi Predict / Compounds / SCHEMBL2938690

SCHEMBL2938690

SCHEMBL2938690

CC1C(=O)N(c2ccc(S(=O)(=O)C(F)(F)F)cc2)C(=O)N1Cc1ccncc1NC(=O)C1CCN(C)CC1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 2/20 0.53
▸ EPHX2 P34913 2/20 0.38
▸ GSK3B P49841 3/20 0.35
▸ CCNE2 O96020 1/20 0.35
▸ CCNE1 P24864 1/20 0.35
▸ CDK2 P24941 1/20 0.35
▸ THRB P10828 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ CHKA P35790 3/20 0.33
▸ CTSS P25774 1/20 0.33
▸ ABL1 P00519 1/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ MAPT P10636 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ DYRK1A Q13627 1/20 0.33
▸ MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2940047 0.92 IGF1R (0.55) IGF1REPHX2GSK3BTHRBCHKA
SCHEMBL2939329 0.87 IGF1R (0.53) IGF1RGSK3BCCNE2CCNE1CDK2
SCHEMBL2935233 0.87 IGF1R (0.38) IGF1RGSK3BTHRBABL1MAPT
SCHEMBL2931354 0.87 GSK3A (0.41) IGF1REPHX2GSK3BKMT2AMAPT
SCHEMBL2939954 0.86 IGF1R (0.60) IGF1RGSK3BCCNE2CCNE1CDK2
SCHEMBL2937893 0.86 IGF1R (0.62) IGF1RGSK3BCCNE2CCNE1CDK2
SCHEMBL2936976 0.85 EPHX2 (0.39) IGF1REPHX2GSK3BCCNE2CCNE1
SCHEMBL2939826 0.84 IGF1R (0.53) IGF1REPHX2
SCHEMBL2938358 0.83 IGF1R (0.53) IGF1REPHX2GSK3BKMT2ADYRK1A
SCHEMBL2937967 0.83 IGF1R (0.56) IGF1RCTSSKMT2AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 — — US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 — — EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 — — US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 — — US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 IGF1R 1595/4885EPHX2 3969/4885GSK3B 799/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA IGF1R 962/4885EPHX2 3424/4885GSK3B 702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.